Effects of oxycodone hydrochloride sustained-release tablets and morphine hydrochloride sustained-release tablets on peripheral blood T cell levels in advanced lung squamous cell carcinoma with moderate to severe cancer pain

  • Juan Yan The First Affiliated Hospital of Hebei North University
  • Zheng-zheng Xie
  • Na Ma
  • Mao-dong Zheng
  • Ting-ting Qiao
  • Yu Wang
Keywords: Lung Squamous Cell Carcinoma, Morphine Hydrochloride Sustained-Release Tablet, Cancer Pain, Oxycodone Hydrochloride Sustained-Release Tablet

Abstract

Objective: To investigate the effects of morphine hydrochloride sustained-release tablets and oxycodone hydrochloride sustained-release tablets on T-cell levels in advanced lung squamous cell carcinoma(LUSC) with moderate to severe cancer pain.

Methods: A retrospective study was used, ninety-eight patients who were admitted to The First Affiliated Hospital of Hebei North University for treatment of advanced LUSC with moderate to severe cancer pain between January 2021 and December 2021 were randomized into two groups(n=49 each) using the sealed envelope system. The reference group was treated with morphine hydrochloride sustained-release tablets, while the experimental group received oxycodone hydrochloride sustained-release tablets to compare pain relief rates(PRRs), levels of T cells, pain intensity, et al. Blood samples were collected for lymphocyte levels by flow cytometry.

Results: The experimental group had significantly higher level than the reference group(P<0.05). Before administration, the two groups did not differ greatly in levels of T-cell subsets or pain scores on the visual analog scale(P>0.05, respectively). At 15 days of administration, the Treg level in the experimental group was higher than in the reference group; T helper 17 and 22 cells were reduced in both groups, and the decrease was more pronounced in the experimental group. At seven and 15 days of administration, the experimental group had a VAS score significantly lower than the reference group(P<0.05). The total adverse reaction rate was significantly lower in the experimental group as compared with the reference group(P<0.05).

Conclusions: Oxycodone hydrochloride sustained-release tablets demonstrate desirable efficacy and safety in advanced LUSC with moderate to severe cancer pain by modulating T-cells in the body and improving the PRR.

doi: https://doi.org/10.12669/pjms.39.5.6772

How to cite this: Yan J, Xie Z, Ma N, Zheng M, Qiao T, Wang Y. Effects of oxycodone hydrochloride sustained-release tablets and morphine hydrochloride sustained-release tablets on peripheral blood T cell levels in advanced lung squamous cell carcinoma with moderate to severe cancer pain. Pak J Med Sci. 2023;39(5):1492-1495. doi: https://doi.org/10.12669/pjms.39.5.6772

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published
2023-08-03
How to Cite
Yan, J., Xie, Z.- zheng, Ma, N., Zheng, M.- dong, Qiao, T.- ting, & Wang, Y. (2023). Effects of oxycodone hydrochloride sustained-release tablets and morphine hydrochloride sustained-release tablets on peripheral blood T cell levels in advanced lung squamous cell carcinoma with moderate to severe cancer pain. Pakistan Journal of Medical Sciences, 39(5). https://doi.org/10.12669/pjms.39.5.6772
Section
Original Articles